Analysis of time course and dose effect of tacrolimus on proteinuria in lupus nephritis patients

Chen, Xiao; Wang, Dongdong; Li, Zhiping

doi:10.1111/jcpt.13260

Cited by 13 publications

(6 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When the OFV was increased (>6.63; χ 2 , α=0.01, d.f.=1), significance was achieved in the final model. Our previous studies were mainly based on the methodology used in the present study, and indicated that the present method was reliable and acceptable (32)(33)(34)(35).…”

Section: Effects Of Dapagliflozin On Body Weight In Patients With Typ...mentioning

confidence: 63%

Effects of dapagliflozin on body weight in patients with type 2 diabetes mellitus: Evidence‑based practice

Han,

Li,

et al. 2024

Exp Ther Med

Self Cite

View full text Add to dashboard Cite

The dose-dependent pharmacological response to dapagliflozin in patients with type 2 diabetes mellitus (T2DM) with regard to weight loss remain unknown. The aim of the present study was to investigate the effects of dapagliflozin on weight loss in patients with T2DM. A total of 8,545 patients with T2DM from 24 randomized controlled trials reported in the literature were selected for inclusion in the study. Data from these trials were analyzed using maximal effect (E max ) models with nonlinear mixed effects modeling; the evaluation index was the body weight change rate from baseline values. Patients treated with 2.5 mg/day dapagliflozin exhibited an E max of -3.04%, and the time taken for therapy to reach half of the E max (ET 50 ) was estimated to be 30.8 weeks for patients treated with this dose. Patients treated with 5, 10 and 20 mg/day dapagliflozin exhibited E max values of -6.57, -4.12 and -3.23%, respectively, and their ET 50 values were estimated to be 27.3, 20.4 and 4.23 weeks, respectively. The data indicated ideal linear relationships between individual predictions and observations, suggesting the optimal fitting of the final models. The present study is the first systematic analysis of the effect of dapagliflozin on weight loss in patients with T2DM. The application of dapagliflozin at 5 mg/day exhibited a greater weight loss effect compared with the other doses used, and the weight loss onset time shortened as the dose of dapagliflozin increased.

show abstract

Section: Effects Of Dapagliflozin On Body Weight In Patients With Typ...mentioning

confidence: 63%

Effects of dapagliflozin on body weight in patients with type 2 diabetes mellitus: Evidence‑based practice

Han,

Li,

et al. 2024

Exp Ther Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…Tacrolimus is a commonly used immunosuppressant in clinical practice that can cure a variety of diseases, such as nephrotic syndrome ( 29 ), myasthenia gravis ( 30 ), ulcerative colitis ( 31 ), systemic lupus erythematosus ( 32 ), lupus nephritis ( 33 ), and autoimmune hepatitis ( 34 ). In addition, tacrolimus also plays an important role in preventing organ rejection after transplantation.…”

Section: Discussionmentioning

confidence: 99%

Optimizing the initial tacrolimus dosage in Chinese children with lung transplantation within normal hematocrit levels

Hu,

He,

Zhang

et al. 2024

Front. Pediatr.

View full text Add to dashboard Cite

BackgroundThe appropriate initial dosage of tacrolimus is undefined in Chinese pediatric lung transplant patients with normal hematocrit values. The purpose of this study is to optimize the initial dose of tacrolimus in Chinese children who are undergoing lung transplantation and have normal hematocrit levels.MethodsThe present study is based on a published population pharmacokinetic model of tacrolimus in lung transplant patients and uses the Monte Carlo simulation to optimize the initial tacrolimus dosage in Chinese children with lung transplantation within normal hematocrit levels.ResultsWithin normal hematocrit levels, for children with lung transplantation who do not carry the CYP3A5*1 gene and have no coadministration with voriconazole, it is recommended to administer tacrolimus at a dosage of 0.02 mg/kg/day, divided into two doses, for children weighing 10–32 kg, and a dosage of 0.03 mg/kg/day, also divided into two doses, for children weighing 32–40 kg. For children with lung transplantation who carry the CYP3A5*1 gene and have no coadministration with voriconazole, tacrolimus dosages of 0.02, 0.03, and 0.04 mg/kg/day split into two doses are recommended for children weighing 10–15, 15–32, and 32–40 kg, respectively. For children with lung transplantation who do not carry the CYP3A5*1 gene and have coadministration with voriconazole, tacrolimus dosages of 0.01 and 0.02 mg/kg/day split into two doses are recommended for children weighing 10–17 and 17–40 kg, respectively. For children with lung transplantation who carry the CYP3A5*1 gene and have coadministration with voriconazole, a tacrolimus dosage of 0.02 mg/kg/day split into two doses is recommended for children weighing 10–40 kg.ConclusionsIt is the first time to optimize the initial dosage of tacrolimus in Chinese children undergoing lung transplantation within normal hematocrit.

show abstract

“…Wang et al reported quantitative efficacy of L-carnitine supplementation on glycemic control in type 2 diabetes mellitus patients [ 74 ]. Chen et al reported analysis of time course and dose effect of tacrolimus on proteinuria in lupus nephritis patients [ 75 ]. Li et al reported quantitative efficacy of soy isoflavones on menopausal hot flashes [ 76 ].…”

Section: Discussionmentioning

confidence: 99%

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Weight in Type 2 Diabetes Mellitus and Therapeutic Regimen Recommendation

Wang

Mao

Yang

et al. 2022

Journal of Diabetes Research

Self Cite

View full text Add to dashboard Cite

Aims. The present study is aimed at exploring the effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on weight in type 2 diabetes mellitus (T2DM) and therapeutic regimen recommendations. Methods. 20,019 patients with T2DM were enrolled. The maximal effect ( E max ) models, whose evaluation index was change rate of body weight from baseline value, were used to analyze data using nonlinear mixed effect modeling (NONMEM). Results. For SGLT-2 inhibitors, canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin and tofogliflozin, the E max , and treatment duration to reach half of the maximal effects (ET50) were -3.72% and 3.35 weeks, -5.59% and 16.8 weeks, -2.84% and 3.42 weeks, -3.43% and 3.09 weeks, -3.04% and 4.38 weeks, and -2.45% and 3.16 weeks, respectively. In addition, for T2DM patients, 100 mg/day canagliflozin needs to be taken 13.4 weeks for the plateau of effect on weight; 10 mg/day empagliflozin needs to be taken 67.2 weeks for the plateau of effect on weight; 5 mg/day ertugliflozin needs to be taken 13.68 weeks for the plateau of effect on weight; 50 mg/day ipragliflozin needs to be taken 12.36 weeks for the plateau of effect on weight; 2.5 mg/day luseogliflozin needs to be taken 17.52 weeks for the plateau of effect on weight; 20 mg/day tofogliflozin needs to be taken 12.64 weeks for the plateau of effect on weight. Conclusions. This was the first study to explore effects of SGLT-2 inhibitors on weight in T2DM; meanwhile, the optimum dosages and treatment durations on weight from canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and tofogliflozin were recommended, respectively.

show abstract

Analysis of time course and dose effect of tacrolimus on proteinuria in lupus nephritis patients

Cited by 13 publications

References 45 publications

Effects of dapagliflozin on body weight in patients with type 2 diabetes mellitus: Evidence‑based practice

Effects of dapagliflozin on body weight in patients with type 2 diabetes mellitus: Evidence‑based practice

Optimizing the initial tacrolimus dosage in Chinese children with lung transplantation within normal hematocrit levels

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Weight in Type 2 Diabetes Mellitus and Therapeutic Regimen Recommendation

Contact Info

Product

Resources

About